Read More Pharma Industry News Wegovy cuts cardiovascular event risk by over half vs tirzepatide—real-world data raises Novo Nordisk lead Discover how Novo Nordisk’s Wegovy reduced heart attack, stroke, and death risk by 57% vs tirzepatide in real-world study. Read the STEER findings now. byPallavi MadhirajuSeptember 1, 2025